drugset / Trial / NCT03697564
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
Phase 2
Completed
2 enrolled
Hitendra Patel
Lustgarten Foundation · collabStand Up To Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone.
Timeline
- Start
- 2019-10-31
- Primary completion
- 2023-04-12
- Completion
- 2023-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabiralizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |